newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

  • IGC Pharma announced that Ascendiant Capital Markets issued a coverage report on the company.
  • The report noted Q2 results and identified positive clinical data and 2025/26 progress as potential stock catalysts.
  • Ascendiant raised its price target for IGC to $4.75 per share.
  • IGC Pharma is a clinical-stage biotechnology firm using AI to develop treatments for Alzheimer's disease & metabolic disorders.
  • The company's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 CALMA trial for agitation in Alzheimer's dementia.
  • The IGC pipeline includes TGR-63 targeting amyloid plaques & early-stage programs focused on neurodegeneration, tau proteins, & metabolic dysfunctions.
  • IGC utilizes AI to accelerate drug discovery, optimize clinical trials, & enhance patient targeting.
  • The press release includes standard disclaimers stating that analyst views do not necessarily represent IGC's views or commitments.
  • Forward-looking statements are subject to risks including regulatory approval, AI algorithm performance, & economic conditions.
  • Investor contact information is provided for Rosalyn Christian & John Nesbett at IMS Investor Relations.